Page 12 - P4304.1-V114 PS Magazine October 2025 (print) 2
P. 12

Top Tips










                 MDS focus
                 Maximising discount on your branded purchases is more important than ever in todays environment.  Taking
                 advantage of MDS deals on expensive branded products will drive extra margin in to the dispensary.  PSUK
                 currently have 25 exclusive MDS deals – not available via any other wholesaler - that deliver on average
                 £800 of benefit to members per month.

                 The table below highlights these deals.  Speak to your Dispensing Doctor Account Manager to make sure
                 you are signed up.

                                PSUK Exclusive Schemes                             PSUK Enhanced Schemes

                       Alimera Sciences                 Ego Pharma                             AbbVie
                  Alliance Pharma - Hydromol        Essential Healthcare                     AgaMatrix
                            Altacor                    Fresenius Kabi                         Almirall
                            Altimed                         GSK                            Bausch & Lomb
                             Alturix                    IPS Pharma                              Cipla

                         Aristo Pharma                    Lifescan                           Dr Reddys
                   Bausch & Lomb - Emerade               MediQuest                           EM Pharma
                             Bayer                       Medlogic                          Gedeon Richter
                        Biocon Biologics              Omega Pharma                          Karo Pharma
                      Brancaster Pharma                    Scholl                   Reckitt Benckiser Healthcare
                           Clinimed                       Typharm                          Stirling Anglian
                            Colgate                   Viatris - Acopair

                       Consilient Health





                 Ipsen - Reduction in MDS on Decapeptyl
                 We would like to remind members that from 15  August 2025, Ipsen reduced the MDS rebate available on
                                                            th
                 Decapeptyl (Triptorelin) to 11.18%.
                 This change meant that Decapeptyl now only breaks even from a profit perspective once clawback in
                 factored in.

                 There are two other GnRH Analogues available that are profitable choices.

                 Staladex (Leuprorelin) attracts a 50% MDS rebate via the Aspire Pharma scheme.

                 AstraZeneca offer a 22.5% rebate on both strength of Zoladex (Goserelin).

                                                              NHS                     NETT    NHS     Profit    MDS
                        Product Description  PIP Code  Supplier  Price  Rebate  WD  Total %  Price  Clawback  Per Pack  Rebate Cap

                 Decapeptyl 3mg SR Injection (1)  2218915  Ipsen  £69.00  11.18%  0%  11.18%  £61.29  £7.71  £0.00  4
                 Decapeptyl 11.25mg SR Injection (1)  3020534  Ipsen  £207.00  11.18%  0%  11.18%  £183.86  £23.14  £0.00  6
                 Decapeptyl 22.25mg SR Injection (1)  3585536  Ipsen  £414.00  11.18%  0%  11.18%  £367.71  £46.29  £0.00  4

                 Staladex 11.25mg Implant (1)  1233832 Aspire Pharma  £208.79  50%  0%  50%  £104.40  £23.34  £81.05  100

                 Zoladex 3.6mg Safe System Syringe (1)  89797  Astra Zeneca  £70.00  22.5%  0%  22.5%  £54.25  £7.83  £7.92  -
                 Zoladex 10.8mg Safe System Syringe (1) 2185940  Astra Zeneca  £235.00  22.5%  0%  22.5%  £182.13  £26.27  £26.60  -





                                                                                                                 22/09/2025   10:06:15
         P4304.1-V114 PS Magazine October 2025.indd   12                                                         22/09/2025   10:06:15
         P4304.1-V114 PS Magazine October 2025.indd   12
   7   8   9   10   11   12   13   14   15   16   17